权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

RNA Nanosystem for Posterior Eye Drug Delivery

用于眼后药物输送的 RNA 纳米系统

基本信息

批准号：
10560482
负责人：
Kevin S. Li
金额：
$ 40.13万
依托单位：
UNIVERSITY OF CINCINNATI
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-01-01 至 2024-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10560482
关键词：
3D Print Adverse effects Affect Age related macular degeneration Angiogenesis Inhibitors Animal Model Animals Antibody Therapy Bacteriophages Biological Catalytic RNA Cell Culture Techniques Cells Characteristics Chronic Disease Clinical Trials Confocal Microscopy Cornea Cytomegalovirus Retinitis DNA DNA Packaging Data Development Disease Dissociation Drug Delivery Systems Drug Kinetics Drug Stability Drug or Chemical Eye Eye diseases Fluorescence Microscopy Goals Implant In Vitro Injections Ligands Membrane Methods MicroRNAs Modeling Monitor Monoclonal Antibodies Motor Mus Nanotechnology Nucleotides Oligonucleotides Oryctolagus cuniculus Particle Size Persons Pharmaceutical Preparations Pharmacodynamics Platelet-Derived Growth Factor Polymers Posterior eyeball segment structure Proteins RNA RNA Phages Reporter Research Resistance Retina Route Sclera Silicone Elastomers Small Interfering RNA Structure Structure of retinal pigment epithelium System Technology Therapeutic Therapeutic Agents Therapeutic Effect Thermodynamics Tissues Toxic effect Transfection United States aptamer bevacizumab chemical stability design drug discovery experimental study fluorescence imaging fomivirsen in vivo intravitreal injection macromolecule nanoparticle nanoparticle delivery nanosystems neovascular new technology novel oculomotor particle pegaptanib pharmacokinetics and pharmacodynamics scaffold small molecule systemic toxicity therapeutic RNA uptake

项目摘要

RNA nanotechnology provides molecules that have the simplicity in design with the characteristics of DNA and can be used in therapies. However, a major problem in RNA nanotechnology is that RNA molecules are relatively unstable such as their degradation in vivo and dissociation at ultra-low concentration after administration. Intravitreal injection is the most common method to deliver macromolecular therapeutic agents to the posterior segment of the eye for the treatments of diseases. Repeated intravitreal injection can cause severe adverse effects to the eye. For small drug molecules, systemic administration can be used but this route of administration is complicated by systemic toxicity. There is an unmet need of a more effective drug delivery method in the treatment of posterior eye diseases. We have recently studied RNA nanoparticles derived from the three-way junction (3WJ) of the packaging RNA (pRNA) of bacteriophage phi29 DNA packaging motor for ocular drug delivery. These nanoparticles are thermodynamically and chemically stable both in vitro and in vivo and can harbor multiple modules with different functionalities such as RNA aptamer, reporter moiety, and therapeutic siRNA, miRNA, or other chemical drugs or ligands as subunits all in the same nanoparticles. Our preliminary studies have shown that the pRNA nanoparticles (pRNA nano) were internalized in the cells in the cornea, retinal pigment epithelium, and retina in the eye after subconjunctival injection in mice in vivo. This suggests the potential of subconjunctival injection of pRNA nano as an efficient drug delivery system of RNA-based therapeutic agents to the cells in the posterior segment of the eye: pRNA nano can overcome both the RNA molecule stability and posterior eye delivery problems. The preliminary studies have also suggested that the delivery and retention of pRNA nano are particle size dependent and the existence of an optimal size range for their effective delivery to the cells in the eye. The objectives of the present project are to (a) determine the optimal pRNA nano for ocular drug delivery, (b) demonstrate the ability of pRNA nano to deliver therapeutic agents to treat posterior eye disease, and (c) develop an episcleral implant system for prolonged delivery of these nanoparticles. pRNA nano of different sizes and module subunits will be constructed and evaluated for effective intraocular delivery and therapeutic effects after subconjunctival injection in animal models. The episcleral implant is refillable and is placed on the sclera in the subconjunctival or sub-Tenon pocket to provide sustained delivery of the nanoparticles. The ultimate goal is to develop a platform of ocular drug delivery using the pRNA technology for nucleotide-based therapies via the periocular route (a less invasive approach than intravitreal injection). The present project will examine the feasibility of the combined pRNA nano and episcleral implant approach for the proof of concept of this new technology.

RNA纳米技术提供了具有DNA和DNA特征的简单设计分子